FilippiMRoccaMABarkhofF. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol2012; 11: 349–360.
2.
KornekBStorchMKWeissertR. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol2000; 157: 267–276.
3.
De StefanoNAirasLGrigoriadisN. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs2014; 28: 147–156.
4.
ZivadinovRRederATFilippiM. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology2008; 71: 136–144.
5.
ChenJTCollinsDLAtkinsHL. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology2006; 66: 1935–1937.
6.
SormaniMPArnoldDLDe StefanoN. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol2014; 75: 43–49.
7.
Sastre-GarrigaJTurCParetoD. Brain atrophy in natalizumab-treated patients: A 3-year follow-up. Mult Scler2014.
8.
PaolilloAPiattellaMCPantanoP. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: A monthly MRI study after triple-dose gadolinium-DTPA. J Neurol2004; 251: 432–439.
9.
Vidal-JordanaASastre-GarrigaJPerez-MirallesF. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler2013; 19: 1175–1181.
10.
NakamuraKBrownRAAraujoD. Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: Implications for monitoring atrophy in clinical studies. Neuroimage Clin2014; 6: 166–170.
